Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Degarelix (GnRH antagonist) Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

NCT03112226
View directory record Official record
Conditions
Cognitive Impairment, Estrogen Deficiency, Menopause, Endothelial Dysfunction, Vascular Stiffness
Interventions
GnRHant + E2, GnRHant + Placebo
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 7, 2026, 4:49 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

NCT02478775
View directory record Official record
Conditions
Obesity, Fertility
Interventions
Degarelix (GnRH antagonist), recombinant FSH, Cetrorelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 7, 2026, 4:49 PM EDT
Terminated Phase 3 Interventional Results available

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

NCT02663908
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
Male only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 7, 2026, 4:49 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

NCT05057546
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Women, Aging
Interventions
GnRH antagonist
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 7, 2026, 4:49 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

NCT07313241
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bioenergetic Effects of Aging and Menopause (BEAM)

NCT04043520
View directory record Official record
Conditions
Menopause, Obesity, Abdominal, Aging, Weight Gain
Interventions
GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 7, 2026, 4:49 PM EDT
Active, not recruiting Not applicable Interventional Results available

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

NCT05628363
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy
Device · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 7, 2026, 4:49 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

NCT07335796
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986165, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

NCT02135445
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-385, Degarelix
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 7, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
Drug · Radiation
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 7, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 7, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

NCT01751451
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 7, 2026, 4:49 PM EDT
Recruiting Phase 2Phase 3 Interventional

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT04787744
View directory record Official record
Conditions
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
Procedure · Radiation · Other + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Completed Phase 1 Interventional

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

NCT05617885
View directory record Official record
Conditions
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
Interventions
Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix
Drug
Lead sponsor
Praful Ravi, MB BCHir, MRCP
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 7, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118
View directory record Official record
Conditions
Prostate Cancer
Interventions
DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 7, 2026, 4:49 PM EDT